Guidance slashed, court delays drag—brand intact but visibility zero
A court-ordered plant closure cost ₹250–260 Cr in revenue this quarter and forced management to cut FY27 guidance by 28–32% mid-year. The underlying business (Karnataka +30%, Odisha steady) suggests the franchise is sound—but the MP restart timeline is opaque, and the market is repricing accordingly.
₹609.2 Cr
-31.1% YoY; MP closure explains most of the collapse
₹1.6 Cr
-96.3% YoY; OPM 2.5%, NPM 0.3%
₹250–260 Cr
6-month plant closure ongoing
₹1,000–1,100 Cr
Cut from ₹1,400–1,500 Cr; 28–32% downgrade
Where the quarter really broke
The Madhya Pradesh plant—Som's largest facility—has been court-ordered shut for 6 months. The closure is sub judice, meaning management cannot publicly disclose the timeline or specifics. The result: ₹250–260 Cr in quarterly revenue offline, and ₹6–7 Cr in fixed costs (salaries, interest, utilities) continuing on zero output. Additionally, ₹25 Cr in finished goods inventory is trapped in Bhopal with roughly 1 month of shelf life remaining. Everything else in the quarter—the margins, the profit collapse, the guidance cut—flows directly from this single operational failure.
It is crucial to separate what this means: the headline numbers are real and terrible, but they are entirely explained by one temporary (albeit opaque) event. Remove the MP disruption and the underlying business—regional recovery in Karnataka and Odisha, premiumization momentum, cash generation, the UP platform build—shows structural resilience. The market has seized on that gap and marked down the stock accordingly.
Management's claims vs. what holds up
MP closure cost ₹250–260 Cr revenue
SupportedQ1 total revenue ₹609.2 Cr, down 31.1% YoY. Management quantified the MP impact directly at ₹250–260 Cr.
Recovery in Karnataka (+30%) and Odisha (~40% of prior) shows brand strength
SupportedHassan (Karnataka) operating at 60% utilization YoY; Odisha at 70%. Volume recoveries in both states confirmed independently.
UP capex ₹300 Cr funded without external debt
SupportedGross debt only 0.31x equity; only ₹10 Cr increase in debt despite capex. Operating cash flow ₹28 Cr in Q1.
The underlying business remains strong
ContradictedQ1 OPM 2.5%, NPM 0.3% vs. prior ~10% EBITDA margin target. Margin collapse is at odds with 'strong' framing.
FY27 revenue guidance of ₹1,400–1,500 Cr remains achievable
ContradictedManagement revised FY27 guidance mid-quarter to ₹1,000–1,100 Cr; a cut of ₹300–500 Cr.
Once the consumer moves away to a different brand…it's not a very easy task to get them back. But we are confident because our brands have that inherent strength.
What changed on this call vs. prior quarter
FY27 revenue guidance: Cut from ₹1,400–1,500 Cr (stated on FY26 calls) to ₹1,000–1,100 Cr (mid-quarter revision). The 28–32% downgrade reflects the MP closure extending longer than initially expected. MP restart timeline: On the prior call, management promised a restart within 15 days. Six months have now passed with no public update. The matter is sub judice, so the company cannot disclose specifics—but the prior commit has evaporated. Analysts pressed hard on this (Manoj Pal asked directly); management deflected and said it was 'hopeful' for August resolution with no guarantee. Andhra Pradesh entry: Originally promised for Q1 FY27; delayed to first week September 2026 due to state excise authority and corporate permission delays. UP ramp timeline: Management now expects 3–4 years to reach peak 10M case utilization at the UP facility (commissioned June 2026). This is slower than the implied ramp suggested on earlier calls.
How the street is positioned
Price action & market verdict: The result was announced on 2026-08-20 at a pre-result close of ₹73.52. Day 1 saw a -2.75% selloff (to roughly ₹71.50), which held steady through day 3 (+0.92%, recovery attempt) and day 5 (+0.65%, faded). The market's own verdict: the initial shock held; no re-rating upside materialized. The sell-off was measured but decisive, reflecting the street's refusal to buy the 'underlying strength' narrative without visibility into MP's restart.
Valuation & drawdown context: The stock now trades at ₹73.51, down 45% from its all-time high of ₹134.02. However, it is up 19% off its 52-week low of ₹61.8, and currently trades above both the 20-day and 50-day simple moving averages (₹72.74 and ₹71.96, respectively) but below the 200-day average of ₹88.18. RSI is neutral at 55.2. This suggests the stock is not yet oversold on a technicals basis, but momentum has decisively turned. If downside news emerges (further MP delay), the next major support is ₹61.8 (the 52-week low).
Institutional positioning (FII/DII exodus): This is the most telling market signal. Foreign institutions held 1.20% of Som in Q4 FY26 and have exited to just 0.18% in Q1 FY27—a collapse of 1.02 percentage points in a single quarter. Domestic institutions remain absent (0.00% DII holding). Promoters hold steady at 39.44%. Interpretation: Hot foreign capital is fleeing on execution risk (guidance miss, MP opacity, credibility hit). Domestic institutions are not catching the knife. Promoters are not buying the dip, suggesting either waning confidence or locked-in holdings. The FII exodus is the market's real statement: uncertainty on MP is not a short-term buy.
The bull-bear ledger
Regional recovery intact: Karnataka +30% volume growth, Odisha stable; brand resilience proven despite MP absence
UP capex execution disciplined: ₹300 Cr self-funded, 10M case capacity on time, zero external debt; future growth platform de-risked
Cash generation resilient: ₹28 Cr operating cash in worst-case quarter; gross debt only 0.31x equity
Premiumization momentum: IMFL realization up 3% YoY; portfolio strategy targeting higher margins
MP plant closure entirely opaque: sub judice, no public timeline, management promises broken (15-day restart now 6 months)
Inventory shelf-life crisis: ₹25 Cr finished goods trapped in Bhopal with ~1 month remaining; potential total write-down if MP doesn't restart soon
Fixed cost burden ongoing: ₹6–7 Cr/quarter (salaries, interest, utilities) continue while MP is offline; breakeven math breaks if closure exceeds 12 months
Guidance credibility destroyed: FY27 revenue cut 28–32% mid-year (₹1,400–1,500 Cr → ₹1,000–1,100 Cr); prior guidance not achieved
Market-share erosion risk permanent if closure extends: management admits 'long haul' recovery once consumer switches brands
FII exodus accelerating: Foreign institutions exited 1.02pp in single quarter (1.20% → 0.18%); repricing execution risk
Risks, ranked by severity to a holder
MP restart timeline indefinite (sub judice); no public disclosure
High₹250–260 Cr revenue at stake per quarter. If closure extends beyond 12 months, permanent market-share loss certain and mgmt forecast misses again. Investors cannot price this binary; exit risk highest.
Finished goods inventory shelf-life expiry (~1 month remaining)
High₹25 Cr stuck in Bhopal plant; total write-down likely if MP doesn't restart within 1 month. Direct PAT hit of ₹25 Cr, or 15x this quarter's profit.
Guidance credibility and execution risk elevated
HighPrior FY27 guidance (₹1,400–1,500 Cr) missed mid-year. Prior MP restart promise ('15 days') broken after 6 months. Revised guidance (₹1,000–1,100 Cr) now carries 30% execution risk premium from market. Next miss triggers downside acceleration.
Margin recovery unachieved; input cost inflation not passed
MediumQ1 OPM 2.5%, NPM 0.3% vs. prior ~10% EBITDA target. Raw materials (cans, malt, bottles) up 7.5–8% YoY; no price hike taken. If inflation persists, normalized margins may be 7–8%, not 10%. Upside to 2027 earnings capped.
UP plant slow ramp and near-term margin drag
Medium3–4 years to peak 10M case utilization. UBL also building in UP; market competitive. Near-term ROI pressured by low utilization and brand-building capex. Payback extended.
FII exodus accelerating; liquidity risk
Medium1.02pp collapse in single quarter (1.20% → 0.18%). If further downside news hits (MP delay), panic exit could thin liquidity and force gap-down move. DIIs absent as cushion.
What to watch next
1 · MP plant restart status (Aug–Sep 2026)
Management expressed 'hope' for August resolution. This is the binary event. Court ruling on the Bhopal plant license will resolve 80% of the downside debate. If no news by Sep, and the inventory shelf life expires, cascade risk accelerates. This is the most important item to track.
2 · Andhra Pradesh market launch (first week Sep 2026)
Delayed from Q1 FY27, now scheduled for first week September. Execution here will signal whether management can deliver on post-disruption priorities. Success = confidence in UP ramp. Failure or further delay = credibility hit.
3 · Q2 FY27 revenue print (Oct 2026, likely)
Will show whether MP recovery is beginning. If Q2 revenue is ₹750–850 Cr (indicating MP coming back online), thesis holds and revised FY27 guidance (₹1,000–1,100 Cr) is on track. If flat or down further, binary failure mode has materialized.
4 · Margin guidance reset (next earnings call, post-Q2)
Management deferred EBITDA margin guidance to 'next call'. Prior ₹10% EBITDA target now looks unachievable; expect revised 7–8% guidance. If guidance rises (indicating cost cuts or pricing traction), execution credibility improves. If guidance drops further, input cost headwind confirmed.
Som Distilleries is a fundamentally sound regional player—brand-strong, operationally disciplined, and positioned for long-term growth via UP and Andhra Pradesh. The Q1 result is a step-change downward, but it is entirely explained by the Madhya Pradesh court-ordered closure and is not reflective of the underlying business quality. However, without public visibility into the MP restart timeline (sub judice constraint), the stock cannot be valued on fundamentals; it is instead being repriced as a binary bet on execution. The 45% drawdown from all-time high and the FII exodus (1.02pp) reflect the street's rational skepticism.
The honest read: Hold with clear downside risk management. The bear case (MP closure extends beyond 12 months, market-share loss permanent) has high probability if August passes without court resolution. The bull case (MP restarts Aug–Sep, revised ₹1,000–1,100 Cr FY27 guidance is achievable) is credible but hinges on undisclosed legal outcomes. The single number to track from here is Q2 FY27 revenue—if it shows recovery (₹750–850 Cr range, MP ramp beginning), the thesis holds and further downside is limited. If it stalls, cascade risk materializes and target extends down toward ₹55–60.
Som Distilleries Q1 FY27: consolidated PAT crashes 96% YoY as Bhopal licence woes bite
PAT -96.29% YoY · revenue -31.13% · margins compressing
₹609.19 Cr
-31.13% YoY
₹1.56 Cr
-96.29% YoY
0.26%
-4.5pp YoY
₹0.08
Consolidated revenue came in at ₹609.19 Cr, up 32.9% QoQ but down 31.1% YoY from ₹884.55 Cr, with PAT of ₹1.56 Cr — down 96.3% from ₹42.06 Cr a year ago, though a turnaround from Q4 FY26's ₹56.69 Cr loss. The standalone (Bhopal parent) print is far weaker: revenue collapsed 90.7% YoY to ₹38.93 Cr and PAT fell 96.0% YoY to ₹1.52 Cr, a much sharper drop than the consolidated number — the >59-point gap between standalone and consolidated YoY revenue trends shows subsidiaries, not the parent, are now driving the group's topline.
Q1 FY-2027 vs prior quarters
Consolidated NPM fell to roughly 0.26% from 4.75% a year ago as total expenses of ₹607.27 Cr barely eased against a shrunken revenue base; operating margin similarly compressed to an estimated ~2.5% from ~8% a year ago. The sequential swing out of Q4's loss should be read cautiously rather than celebrated: April-June is India's peak summer season for beer demand, so the QoQ improvement looks like a seasonal artifact rather than an operational turnaround — on the YoY basis that matters more, profitability was nearly wiped out.
The stock went into the print at ₹73.52, up 9.3% over the past month of trading.
What the summary numbers don't show
EPS: ₹0.08 consolidated (vs ₹2.02 YoY), ₹0.07 standalone (vs ₹1.82 YoY)
Results are un-audited (limited review only) — no exceptional items this quarter, unlike Q4 FY26's ₹11.87 Cr exceptional loss
Management anticipates FY27 revenue to be in the range of INR 1,400 to INR 1,500 crores, contingent on the resolution of the Bhopal plant license issue and the successful commissioning of the Uttar Pradesh facility. While EBITDA margins for FY27 are targeted at approximately 10%, a definitive guidance for FY28 is defer
— This quarter: missed
Management's last concall (2 Jun 2026) guided FY27 revenue to ₹1,400-1,500 Cr and ~10% EBITDA margin, explicitly contingent on resolving the Bhopal plant licence and commissioning the Uttar Pradesh facility. That contingency has moved the wrong way: the Bhopal licence application was rejected on 19 Jun 2026, and this filing's auditor review report (Note 4) still flags the MP High Court-ordered renewal process as "currently underway," with management asserting no material going-concern impact. No Q1-specific analyst estimates were found for this small-cap name; the only available data point is a broader FY27 consensus expecting 15-20% PAT growth (Univest), which this quarter's -96% YoY PAT print sits far below. No management press release accompanied this filing, so there is no fresh company commentary to reconcile beyond the auditor's licence note and the subsidiary structure (Woodpecker Distilleries & Breweries, Som Distilleries Odisha, and newly added Woodpecker Greenagri Nutrients), one of which began brewery production on 11 Jun 2026 and appears to be cushioning the standalone shortfall.
W1
Resolution of the Bhopal plant manufacturing licence (MP High Court-ordered renewal "currently underway") after the June 2026 rejection — directly gates management's FY27 revenue guidance of ₹1,400-1,500 Cr
W2
Uttar Pradesh facility commissioning status — the other precondition cited for FY27 guidance, with no update seen this quarter
W3
Whether consolidated profitability (₹1.56 Cr PAT, 0.26% NPM) holds through Q2's seasonally weaker monsoon quarter, given PAT is still down 96% YoY
Clear scan, both statements tie to the paisa; standalone (Bhopal parent) revenue fell -90.7% YoY vs consolidated -31.1% YoY, so subsidiaries are now carrying group topline; no exceptional items in current or year-ago columns (Q4 FY26's ₹11.87 Cr exceptional loss doesn't affect this comparison).
Strong M&A progress, organic growth disappoints
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Prior FY26 guidance for 4000+ Cr consolidated revenue remains unquantified for FY27; organic growth weaker than guided. Margins held as promised.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Structural platform transformation on track (Bliss pharma acquisition closing Sep, Jayhawk strong performer, ETFA/BASQUEVOLT LoI momentum). INR 18K Cr LOI/contract pipeline credible. However, Q1 organic growth (single digit) disappointed vs 25% ± guidance; delivered PAT growth only 6% vs EBITDA +35% due to depreciation drag. Maintain guidance signals management caution. Near-term execution risk around Bliss integration and organic acceleration.
₹655 Cr
Revenue · +34.8% YoY₹51.2 Cr
Reported PAT · +5.7% YoYFlat
Margins · vs guidance: MixedDid the claims hold up?
36% YoY growth in consolidated total income
METDelivered revenue 655 Cr (+34.8% YoY); total income 668 Cr (+36% YoY)
EBITDA margins maintained at 26%
METEBITDA 175 Cr, 26% margin (vs 129 Cr, 26% YoY); flat YoY
Q1 single-digit organic growth ex-Jayhawk
METQ1 noted as seasonally tepid; Jayhawk 20-22% of revenue (~145 Cr), so standalone growth single digit
PAT growth 6% despite EBITDA +35% due to depreciation and Jayhawk integration
METPAT 51.2 Cr (+5.7% YoY); depreciation spike confirmed as Jayhawk-driven
BASQUEVOLT LoI USD 300M over 10 years, commercialization FY27, 2-3 year meaningful ramp
METLoI signed, tech ready at pilot scale, expects H2 FY27 commercialization, 2-3 years for robust revenue
Earnings quality
What changed since the last call
Organic growth trajectory
DowngradeQ1 FY27 organic (ex-Jayhawk) single digit vs prior guidance 25% ± ; management cited seasonality, but signals Q1 momentum softer than expected.
EBITDA margin guidance
NeutralReaffirmed 24-26% standalone, 22-24% consolidated. Flat vs prior calls; no expansion expected despite higher contribution from higher-margin performance materials.
ETFA & BASQUEVOLT
NewETFA commercialized this Q (first globally). BASQUEVOLT USD 300M LoI signed, starting H2 FY27. Both are material new catalysts not quantified in prior calls.
Capex cycle
NeutralCapex program complete. Guidance INR 70-80 Cr maintenance, no major expansion planned for standalone. Jayhawk unlevered, no incremental capex needed.
The Q&A
Analysts pressed hard on organic growth miss (Q1 single-digit), Bliss timing/integration, and ETFA/BASQUEVOLT scale. Management held firm: Q1 seasonal; Bliss expected Sep close; ETFA/BASQUEVOLT 2-3 year ramps. On guidance, management refused to upgrade; cited confidence in 25% organic ± for full year. Mixed defensiveness—acknowledged seasonality but defensive on Bliss capacity claims (called out as listed entity, deferred deeper color to post-close).
Bliss acquisition status — Tanya Chowdhary, Investec
AnsweredSEBI approval done, open offer concluded Aug 10, procedural closing Q1 Sep expected. Expected fully closed first half September.
Jayhawk contribution Q1 — Tanya Chowdhary, Investec
Answered20-22% of revenue (INR ~145 Cr), EBITDA margins 19-20% (INR ~30 Cr). PAT ~INR 9 Cr after depreciation.
Polymer revenue mix sustainability — Tanya Chowdhary, Investec
AnsweredStandalone 20-25% polymer target, consolidated 30-35%. Agro cycle is softer now but should stabilize; polymers growing faster.
ETFA market size and margin — Meet Vora, JM Financial
PartialUSD 0.5B addressable for ETFA + related molecules. Cost lower, margins better than existing. Can capture 5-10% initially, scale to 15-30%. Margin profile upward biased due to value creation for CDMO customers.
BASQUEVOLT LoI commercialization — Harsh Shah, Axis Capital
AnsweredTech ready, pilot commissioned. Expect H2 FY27 commercialization start. Ramp 2-3 years to robust revenue; will contribute this year but small, ramping gradually.
Organic growth ex-Jayhawk — Darshil Jhaveri, Crown Capital
AnsweredSingle digit. Q1 seasonally tepid for us. Expect to achieve 25% ± guidance going forward.
Bliss CDMO synergies — Ankur Kumar, Alpha Capital
PartialCDMO going forward. Post-consummation, both teams will work rigorously. Today Bliss on its own. Continuing prior hypothesis: improve utilization 30% → 60-70%, translates to expected numbers. Organic growth this Q.
Semiconductors progress — Meet Vora, JM Financial
PartialSemicon growing very fast for us. Strong traction existing + new customers. Jayhawk accelerating (has validated products in semicon). Getting commercial validation. Revenue contribution outlook vague; LinkedIn has details.
Agro business outlook — Probal Sen, ICICI Securities
AnsweredRobust demand recovery; delivering on start-of-year forecast. Will remain stable but contribution declining (due to pharma/polymers growing faster, not agro slowing).
Capex guidance FY27-28 — Meet Vora, JM Financial
AnsweredJayhawk well capitalized, unlevered, can fund own capex. Anupam capex: major cycle complete, INR 70-80 Cr for maintenance/replacement only. No significant capex needed.
Guidance
FY27 organic growth 25% ± couple points
MediumQ1 single digit due to seasonality; expect acceleration. Ex-Jayhawk, organic target 25%; Jayhawk adds 10-15% additional growth.
Standalone EBITDA 24-26%; consolidated 22-24%
HighReaffirmed from prior calls. Flat vs Q1 26%; managing mix headwinds from agro softness and polymer growth.
INR 70-80 Crores FY27 (maintenance level only)
HighMajor capex cycle complete. No significant expansion capex planned for Anupam standalone. Jayhawk self-funding.
Risks the call surfaced
Organic growth execution
HighQ1 organic (ex-Jayhawk) single digit vs 25% ± FY27 target. Agro softer, pharma/polymers growing faster but not enough to offset. Expansion acceleration must occur post-Q1.
EBITDA margin compression risk
MediumConsolidated EBITDA 26% flat despite shift to higher-value performance materials and Jayhawk (19-20% margin). Polymer growth diluting standalone margin profile. Consolidated guidance 22-24%, tighter than standalone.
Bliss integration and capacity utilization
MediumBliss currently ~30% utilization. Management targeting 60-70% over 2-3 years. Integration unproven (acquisition closing only first-half Sep). CDMO synergies contingent on Anupam sales/marketing traction. Organic growth Q1 soft; Bliss revenue accretion needed but timing uncertain.
BASQUEVOLT/ETFA timeline and ramp execution
MediumBASQUEVOLT LoI just signed; USD 300M over 10 years = ~INR 2400 Cr lifetime. 2-3 year ramp before meaningful revenue. ETFA just commercialized; management targeting 5-10% to 15-30% of USD 0.5B market, but market validation and customer adoption timelines unproven.
Order book execution and new product commercialization
MediumOrder book INR 400+ Cr prior year now 25% of revenue. Expected to reach 30%. Multiple new products scheduled for commercialization FY27+. Timing and ramp of each product execution-dependent. No single large contract details shared.
Management
Score 7/10. Transparent on Q1 seasonality and organic growth miss. Defensive but not evasive on Bliss (cited listed-entity sensitivity appropriately). Detailed on technical ETFA/flow chemistry and BASQUEVOLT LoI mechanics. Some vagueness on semicon segment color and Bliss synergy quantification (pre-close caution justified). Strong track record: Jayhawk performing (19-20% EBITDA, 20-22% revenue), Tanfac integrating, order book ramping. Q1 organic growth disappointing vs expectations, but seasonality is credible. Capex cycle on track. Margins maintained at guidance.
1 · Sep 2026
Bliss GVS acquisition close; integration planning begins
2 · H2 FY27
ETFA flow chemistry commercialization; BASQUEVOLT production start
3 · FY27 end
Order book revenue ramp; new product commercialization across pipeline
Near-term execution risk around Bliss integration and organic acceleration.